1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited

2,434.70
INR
-29.05
(-1.18%)
59.95EPS
40.87P/E
415.04BMarket Cap
Nov 03Next Earn
GlaxoSmithKline Pharmaceuticals Limited
BSE:GLAXO
(Bombay Stock Exchange)

Recent

price

2,434.70

P/E

ratio

40.87

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
126.98
142.27
156.45
150.81
- -
158.45
171.69
165.64
182.92
188.84
171.15
192.68
190.45
203.17
219.95
224.76
223.12
Revenue per Share
33.09
25.3
33.17
28.43
- -
22.2
19.88
20.7
26.29
5.5
21.14
100.04
36.05
34.83
54.76
61.15
59.95
Basic EPS, GAAP
27.03
17.31
18.51
16.61
- -
8.2
13.83
27.91
24.17
19.6
31.5
45.81
25.98
32.51
74.68
50.06
- -
Free Cash Flow per Basic Share
14.94
19.93
22.32
24.87
- -
31.25
25
15
17.5
20
39.97
29.91
90.05
31.97
44.24
42.15
- -
Dividend per Share
115.2
114.26
118.46
117.45
144.27
128.88
118.46
121.44
126.31
107.47
87.26
157.19
102.79
104.93
115.19
133.84
- -
Book Value per Share
115.2
114.26
118.46
117.45
144.27
128.88
116.56
117.15
122.44
104.54
84.7
155.16
100.77
103.54
114.4
133.46
- -
Tangible Book Value per Share
169
169
169
169
85
169
169
169
169
169
169
169
169
169
169
169
169
Basic Weighted Avg Shares
21,511
24,102
26,504
25,548
- -
26,843
29,085
28,061
30,987
31,991
28,994
32,641
32,264
34,418
37,260
38,076
37,802
Sales/Revenue/Turnover
40.52
32.76
30.07
20.33
- -
17.21
13.5
16.98
17.96
18.36
17.92
21.41
23.2
24.36
29.91
32.77
31.85
Operating Margin (%)
176
204
178
199
- -
249
263
380
486
827
786
682
658
697
668
664
649
Depreciation Expense
5,606
4,286
5,619
4,817
- -
3,761
3,368
3,507
4,454
932
3,581
16,947
6,107
5,900
9,276
10,360
10,157
Net Income, GAAP
33.66
29.13
32.66
32.3
- -
34.97
34.11
35.05
34.76
69.52
36.72
51.12
27.35
27.72
26.38
26.32
26.1
Effective Tax Rate (%)
26.06
17.78
21.2
18.85
- -
14.01
11.58
12.5
14.37
2.91
12.35
51.92
18.93
17.14
24.89
27.21
26.87
Profit Margin (%)
16,646
17,455
18,103
17,350
20,742
15,888
9,524
5,816
5,551
7,506
8,481
20,096
11,679
12,735
15,047
18,280
- -
Working Capital
52
46
41
36
26
16
10
6
2
269
202
76
35
65
25
173
- -
LT Debt
19,516
19,357
20,068
19,897
24,441
21,832
20,069
20,573
21,398
18,206
14,783
26,630
17,413
17,776
19,513
22,674
- -
Total Equity
30.23
16.97
22.69
18.55
- -
13.05
13.86
15.24
17.11
3.53
11.99
15.05
21.73
24.4
36.16
35.27
- -
Return on Invested Capital (%)
29.91
22.01
28.45
24.06
- -
16.25
16.07
17.25
21.23
4.74
21.35
80.83
27.57
33.28
49.42
48.71
- -
Return on Capital (%)
30
22.05
28.5
24.1
- -
16.26
16.08
17.26
21.22
4.71
21.71
81.85
27.73
33.53
49.75
49.11
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
160
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
173
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
169
169
169
Market Capitalization
418,594
386,822
415,045

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
36,071
- -
Cash, Cash Equivalents & STI
- -
27,563
- -
Accounts Receivable, Net
- -
2,731
- -
Inventories
- -
4,576
- -
Total Current Liabilities
- -
17,791
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
160
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.83%
14.72%
16.2%
Free Cash Flow
32.29%
24.8%
-32.97%
Net Income, GAAP
60.06%
74.95%
11.69%
Sales/Revenue/Turnover
3.77%
5.71%
2.19%
Total Cash Common Dividend
21.59%
29.02%
-4.72%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
8,147
10,108
9,494
9,744
37,260
2026
8,052
- -
10,413
9,953
38,076
2027
9,384
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
10.76
14.91
13.57
15.52
54.76
2026
12.1
- -
17.45
16.4
61.15
2027
14
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
44.24
2026
- -
- -
- -
- -
42.15
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
GlaxoSmithKline Pharmaceuticals Limited is a prominent healthcare enterprise focused on the research, development, production, and distribution of pharmaceutical remedies and immunizations, primarily within India. The company delivers a broad spectrum of prescription medications for various therapeutic needs including anti-infectives, respiratory conditions, dermatological issues, women's health, diabetes management, cardiovascular ailments, and rare diseases. Additionally, its portfolio encompasses a comprehensive array of vaccines. Products are offered under well-recognized brands such as Augmentin, Calpol, Ceftum, Eltroxin, Infanrix Hexa, Synflorix, Havrix, Menveo, Nucala, and Trelegy Ellipta. With a history dating back to its incorporation in 1924, the entity was initially known as H. J. Foster & Co. Limited and later SmithKline Beecham Pharmaceuticals India Ltd., before adopting its current name in 2001. Headquartered in Mumbai, India, GlaxoSmithKline Pharmaceuticals Limited maintains manufacturing operations in Nashik, Maharashtra, and continues to expand its offerings, including a recent foray into oncology in the Indian market.